Order Article Reprints

Rittberg R, Leung B, Shokoohi A, Pender A, Wong S, Al-Hashami Z, Wang Y, Ho C. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current Oncology. 2023; 30(6):5299-5308. https://doi.org/10.3390/curroncol30060402

Rittberg, Rebekah, Bonnie Leung, Aria Shokoohi, Alexandra Pender, Selina Wong, Zamzam Al-Hashami, Ying Wang, and Cheryl Ho. 2023. "Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy" Current Oncology 30, no. 6: 5299-5308. https://doi.org/10.3390/curroncol30060402

Rittberg, R., Leung, B., Shokoohi, A., Pender, A., Wong, S., Al-Hashami, Z., Wang, Y., & Ho, C. (2023). Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy. Current Oncology, 30(6), 5299-5308. https://doi.org/10.3390/curroncol30060402